Critical Evaluation of Latanoprostene Bunod in the Treatment of Glaucoma

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2016 Nov 2

PMID 27799730

Citations 14

Authors

Giancarlo A Garcia

Philip Ngai

Sameh Mosaed

Ken Y Lin

Affiliations

Soon will be listed here.

Abstract

Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated.

Citing Articles

Marine Phytoplankton Bioactive Lipids and Their Perspectives in Clinical Inflammation.

Cutolo E, Campitiello R, Di Dato V, Orefice I, Angstenberger M, Cutolo M Mar Drugs. 2025; 23(2).

PMID: 39997210 PMC: 11857744. DOI: 10.3390/md23020086.

The Application of Nitric Oxide for Ocular Hypertension Treatment.

Han B, Song M, Li L, Sun X, Lei Y Molecules. 2021; 26(23).

PMID: 34885889 PMC: 8659272. DOI: 10.3390/molecules26237306.

Novel Thiol Containing Hybrid Antioxidant-Nitric Oxide Donor Small Molecules for Treatment of Glaucoma.

Amankwa C, Gondi S, Dibas A, Weston C, Funk A, Nguyen T Antioxidants (Basel). 2021; 10(4).

PMID: 33917924 PMC: 8068288. DOI: 10.3390/antiox10040575.

Evaluation of the IOP-Lowering Effect of a Multi-Pressure Dial at Different Negative Pressure Settings.

Swan R, Ferguson T, Shah M, Muir K, Samuelson T, Ahmed I Transl Vis Sci Technol. 2020; 9(12):19.

PMID: 33240572 PMC: 7673999. DOI: 10.1167/tvst.9.12.19.

Deconstructing aqueous humor outflow - The last 50 years.

Kaufman P Exp Eye Res. 2020; 197:108105.

PMID: 32590004 PMC: 7990028. DOI: 10.1016/j.exer.2020.108105.

References

Sagara T, Gaton D, Lindsey J, Gabelt B, Kaufman P, Weinreb R . Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999; 117(6):794-801. DOI: 10.1001/archopht.117.6.794. View

Arnal J, Dinh-Xuan A, Pueyo M, Darblade B, Rami J . Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci. 1999; 55(8-9):1078-87. PMC: 11146781. DOI: 10.1007/s000180050358. View

Chuman H, Chuman T, Nao-i N, Sawada A . The effect of L-arginine on intraocular pressure in the human eye. Curr Eye Res. 2000; 20(6):511-6. View

Kim J, Lindsey J, Wang N, Weinreb R . Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001; 42(7):1514-21. View

Abelson M, Netland P, Chapin M . Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model. Adv Ther. 2002; 18(6):282-97. DOI: 10.1007/BF02850198. View

Kotikoski H, Alajuuma P, Moilanen E, Salmenpera P, Oksala O, Laippala P . Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. J Ocul Pharmacol Ther. 2002; 18(1):11-23. DOI: 10.1089/108076802317233171. View

Weinreb R, Lindsey J . Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002; 43(3):716-22. View

Pisella P, Pouliquen P, Baudouin C . Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86(4):418-23. PMC: 1771067. DOI: 10.1136/bjo.86.4.418. View

Schlotzer-Schrehardt U, Zenkel M, Nusing R . Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002; 43(5):1475-87. View

10.

Kass M, Heuer D, Higginbotham E, Johnson C, Keltner J, Miller J . The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-13; discussion 829-30. DOI: 10.1001/archopht.120.6.701. View

11.

Spooner J, Bullano M, Ikeda L, Cockerham T, Waugh W, Johnson T . Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 2002; 8(10 Suppl):S262-70. View

12.

Sjoquist B, Stjernschantz J . Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002; 47 Suppl 1:S6-12. DOI: 10.1016/s0039-6257(02)00302-8. View

13.

Sharif N, Kelly C, Crider J . Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002; 18(4):313-24. DOI: 10.1089/10807680260218489. View

14.

Taylor S, Galbraith S, Mills R . Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002; 18(5):401-9. DOI: 10.1089/10807680260362687. View

15.

Anthony T, Lindsey J, Weinreb R . Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002; 43(12):3705-11. View

16.

Schneemann A, Dijkstra B, van den Berg T, Kamphuis W, Hoyng P . Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion. Graefes Arch Clin Exp Ophthalmol. 2002; 240(11):936-41. DOI: 10.1007/s00417-002-0559-7. View

17.

Leske M, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E . Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1):48-56. DOI: 10.1001/archopht.121.1.48. View

18.

Feldman R . Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003; 19(1):23-35. DOI: 10.1089/108076803762718088. View

19.

Heimark R, Kaochar S, Stamer W . Human Schlemm's canal cells express the endothelial adherens proteins, VE-cadherin and PECAM-1. Curr Eye Res. 2003; 25(5):299-308. DOI: 10.1076/ceyr.25.5.299.13495. View

20.

Nelson P, Aspinall P, Papasouliotis O, Worton B, OBrien C . Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003; 12(2):139-50. DOI: 10.1097/00061198-200304000-00009. View